Helping Your Patients Save Money on Zepbound: A Provider's Guide

Zepbound (tirzepatide) is one of the most effective obesity treatments available today — but its list price puts it out of reach for many patients without strategic support. This guide walks prescribers through the full landscape of cost-reduction options: patient assistance programs, prior authorization strategies, formulary navigation, pharmacy price variation, and how services like FindUrMeds can help your patients stay on therapy without breaking the bank.

---

The Real Cost Burden Your Patients Are Facing

Let's start with the number that stops patients in their tracks: Zepbound's list price runs approximately $1,060–$1,100 per month without insurance coverage. For a medication that requires ongoing use to maintain its benefits, that's not a one-time sticker shock — it's a recurring financial barrier.

Even patients with commercial insurance often face high cost-sharing through tiered formularies, prior authorization hurdles, or step therapy requirements. And for the large share of your patients on Medicare Part D, coverage remains limited under current policy — Medicare does not cover GLP-1 medications prescribed primarily for weight loss, though this landscape may shift in coming years.

The result? Many patients either never start Zepbound, ration their doses, or abandon therapy within a few months — right before they would have seen the most meaningful results.

As their prescriber, you're in the best position to help them navigate this. Here's how.

---

Understand Your Patient's Insurance Situation First

Before diving into cost-saving strategies, take a moment to identify which coverage category your patient falls into. Your approach will differ significantly depending on their situation.

• Commercial insurance (employer or ACA marketplace): Most likely to have some pathway to coverage, especially if obesity-related comorbidities are present.
• Medicare Part D: Currently does not cover tirzepatide for weight management. Some patients may have access through Medicare Advantage plans with supplemental obesity benefits — worth investigating on a plan-by-plan basis.
• Medicaid: Coverage varies significantly by state. Some states cover GLP-1s for obesity with appropriate documentation; others do not.
• Uninsured or underinsured: Manufacturer savings programs and cash-pay pharmacy options become the primary levers.

Knowing where your patient stands lets you target the right tools immediately rather than sending them through a trial-and-error process on their own.

---

Eli Lilly's Patient Assistance Programs

Eli Lilly offers two key programs that your team should have on hand as a standard part of Zepbound prescribing.

Lilly's Zepbound Savings Card (Commercial Insurance)

For patients with commercial insurance, the Lilly savings card can reduce out-of-pocket costs to as low as $25 per month for eligible patients. This is one of the most impactful cost tools available for commercially insured patients who have Zepbound covered on their formulary, even at a higher tier.

Patients can enroll at Lilly's website directly, and your office can flag this resource during the visit rather than leaving patients to find it on their own.

Key caveat: This savings card is not valid for Medicare, Medicaid, or other government-funded insurance programs. Eligibility is also subject to income and insurance criteria that can change — always direct patients to confirm current terms.

LillyCaresFoundation (Uninsured / Low-Income Patients)

For patients who are uninsured or cannot afford their medication even with insurance, the Lilly Cares Foundation Patient Assistance Program provides Zepbound at no cost to qualifying individuals. Income eligibility thresholds apply.

Your office can help initiate this process — having a staff member familiar with the application workflow can dramatically increase uptake among the patients who need it most.

---

Prior Authorization: Win More of Them

Prior authorization for Zepbound is nearly universal, and a poorly documented PA request is the fastest way to delay or deny access. Here's how to strengthen your submissions.

Document Obesity as a Diagnosis, Not a Symptom

Make sure obesity (BMI ≥ 30, or ≥ 27 with a qualifying comorbidity) is explicitly listed as a primary diagnosis in your notes and on the PA form — not buried as a secondary condition. Many plans require this documentation to be clear and current.

List Comorbidities in Detail

Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity — including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Each documented comorbidity strengthens the medical necessity case.

Document Prior Treatment History

Most payers require evidence of prior failed interventions: structured diet programs, behavioral counseling, or other weight management medications. Have your clinical notes reflect this history explicitly, including dates and outcomes.

Address Step Therapy Requirements Head-On

Some plans require patients to have tried — and failed — other agents before approving Zepbound. If your patient has a history with older medications (phentermine, orlistat, naltrexone/bupropion, liraglutide), document it. If step therapy requirements would pose a clinical risk or have already been met, prepare a letter of medical necessity that makes this explicit.

Appeal Denials Promptly

Initial PA denials are not final. If you receive a denial, request the specific reason in writing and respond with targeted clinical documentation. Peer-to-peer review with the plan's medical director can also be effective, particularly for patients with significant cardiovascular or metabolic risk.

---

Formulary Navigation: Know the Tier, Know the Strategy

Zepbound's formulary placement varies considerably across commercial plans. On many formularies, it sits at Tier 3 or Tier 4 — meaning meaningful cost-sharing even after the PA is approved.

A few strategies worth exploring with your patients:

• Formulary exception requests: If tirzepatide is not on formulary or is placed at a restrictive tier, you can request a formulary exception on grounds of medical necessity — particularly if formulary alternatives are contraindicated or have been ineffective.
• Open enrollment counseling: If your patient's current plan has poor Zepbound coverage, help them understand that plan selection at open enrollment can dramatically affect their annual out-of-pocket costs. Connecting them with a benefits counselor or health insurance navigator can pay dividends.
• Specialty pharmacy routing: Some payers route Zepbound through specialty pharmacies rather than retail chains. Make sure your patient knows where their plan requires them to fill.

---

Are There Generic or Lower-Cost Alternatives?

There is currently no FDA-approved generic version of tirzepatide, and given the complexity of the molecule, a generic is not expected in the near future.

Compounded tirzepatide has been widely discussed — and during documented FDA shortage periods, some compounding pharmacies legally produced tirzepatide-based formulations. However, as of 2025, FDA has determined that tirzepatide is no longer in shortage, which significantly restricts the legal availability of compounded versions. Advise patients to be cautious about compounded sources that may not meet FDA safety and efficacy standards.

For patients who cannot access or afford Zepbound, there are other GLP-1 and weight management options worth a clinical conversation. alternatives to Zepbound

---

Pharmacy Price Variation: It's Bigger Than Patients Expect

Even for a brand-name drug like Zepbound, cash prices and insurance cost-sharing can vary meaningfully across pharmacies. Major chains — CVS, Walgreens, Walmart, Costco, Kroger — may price differently, and warehouse clubs like Costco and Sam's Club are often lower for members paying cash.

GoodRx and similar discount platforms can provide some reduction from list price for cash-paying patients, though the savings on a medication at this price point are less dramatic than with generics.

The bigger issue for many patients isn't price alone — it's finding a pharmacy that actually has Zepbound in stock. Tirzepatide has faced persistent supply challenges at the retail level, and patients often spend hours calling pharmacies only to come up empty.

This is where FindUrMeds can make a meaningful difference for your patients.

---

How FindUrMeds Helps With Both Access and Affordability

FindUrMeds is a pharmacy locator service that contacts pharmacies on your patient's behalf — searching across 15,000+ locations nationwide, including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — to find their prescription in stock nearby, typically within 24–48 hours.

For Zepbound patients specifically, FindUrMeds addresses two compounding frustrations:

1. Stock availability: Patients don't have to spend their lunch break calling a dozen pharmacies. FindUrMeds does that work for them and finds where their dose is actually available.
2. Price comparison across locations: Because costs can vary by pharmacy, finding the right in-stock location can also mean finding a better price point — especially relevant for cash-pay patients.

With a 92% success rate and trust from 200+ healthcare providers, FindUrMeds is a practical referral you can make at the point of prescribing. For patients already struggling with the complexity of getting Zepbound covered, eliminating the stock-hunting burden matters.

For more on helping your patients navigate the Zepbound supply chain, see how to help patients find Zepbound in stock.

---

A Quick Summary for Your Prescribing Workflow

Here's a practical checklist to keep at hand when prescribing Zepbound:

• ☐ Confirm insurance type and current formulary status
• ☐ Document obesity diagnosis, BMI, and all relevant comorbidities
• ☐ Record prior weight management treatment history
• ☐ Submit PA with detailed medical necessity documentation
• ☐ Enroll eligible commercial patients in the Lilly savings card
• ☐ Refer uninsured/low-income patients to Lilly Cares Foundation
• ☐ Discuss formulary exception or step therapy options if needed
• ☐ Advise patients on pharmacy access challenges and refer to FindUrMeds

---

FAQ

Can my patients on Medicare get any help paying for Zepbound?

Currently, Medicare Part D does not cover tirzepatide prescribed for weight loss. Some Medicare Advantage plans may offer supplemental benefits — it's worth checking individual plan formularies. The Lilly savings card is not valid for Medicare beneficiaries. Patients in this situation may want to explore the Lilly Cares Foundation program if they meet income eligibility, or discuss alternative treatment options with you.

What's the strongest documentation I can include in a PA submission for Zepbound?

Lead with a clear obesity diagnosis (ICD-10 code E66.xx), documented BMI, all relevant comorbidities with supporting lab work or specialist notes, a history of prior weight management interventions with outcomes, and a clinical rationale for why Zepbound specifically is indicated. A well-structured letter of medical necessity attached to the PA form significantly improves approval rates.

Is compounded tirzepatide a safe and legal option for my patients?

Compounded tirzepatide was available through certain pharmacies during the FDA's documented shortage period. As of 2025, FDA has determined tirzepatide is no longer in shortage, which has curtailed legal compounding of this medication. Patients may still encounter offers for compounded tirzepatide online — advise caution, as these sources may not meet safety and quality standards. Discuss the clinical and legal landscape openly with patients who ask.

My patient was approved but can't find Zepbound in stock anywhere nearby. What should I tell them?

Zepbound supply at the retail level has been inconsistent in many markets. Advise patients not to wait on refills until the last dose — building in lead time helps. For patients actively struggling to locate their prescription, FindUrMeds can contact pharmacies across 15,000+ locations on their behalf and typically find stock within 24–48 hours. It's a practical referral that can prevent dangerous gaps in therapy.

---

Need help finding Zepbound in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Zepbound Near You →

---

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →